Physician profile
Sarah Leite
NPI 1083637516
$6,119.82
in general payments reported to CMS, 2019-2025
31 companies · $1,381 in 2025
The $1,381 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,197 · 2020: $603 · 2021: $317 · 2022: $675 · 2023: $1,070 · 2024: $877 · 2025: $1,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,327.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,252.69 | 2019-2023 | |
| Exeltis, USA INC. | $949.83 | 2019-2025 | Slynd, Nuvessa, Tyblume |
| Astellas Pharma US INC | $739.44 | 2019-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $514.12 | 2022-2025 | |
| Coopersurgical, INC. | $443.88 | 2020-2025 | Paragard T 380a, Paragard T 380a |
| Sumitomo Pharma America, INC. | $303.10 | 2023-2025 | Myfembree, Gemtesa |
| Exact Sciences Corporation | $246.13 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $160.83 | 2021-2025 | |
| Allergan, INC. | $154.51 | 2019-2020 | |
| Aspira Women'S Health INC | $149.61 | 2024-2025 | Ova1 |
| Hologic Sales and Service, LLC | $142.58 | 2023 | Acessa Provu System |
| Millicent US INC | $136.70 | 2019-2025 | Intrarosa, Femlyv, Femring |
| Vertical Pharmaceuticals, LLC | $130.93 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.15 | 2019-2025 | |
| Organon LLC | $98.10 | 2022-2024 | Nexplanon, Nuvaring |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $71.60 | 2021-2022 | |
| Lupin INC. | $69.93 | 2019-2021 | |
| Evofem Biosciences, INC. | $63.58 | 2020-2022 | |
| Sage Therapeutics, LLC | $60.52 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $52.84 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $52.41 | 2020-2023 | Gardasil 9 |
| Duchesnay USA Incorporated | $34.81 | 2019 | |
| Agile Therapeutics, INC. | $33.45 | 2021 | |
| Shield Therapeutics INC | $24.64 | 2023 | Accrufer |
| Coloplast Corp | $24.53 | 2020 | |
| Urovant Sciences INC | $23.20 | 2022 | |
| Meditrina | $22.13 | 2025 | |
| Boston Scientific Corporation | $18.19 | 2024 | Opticross 35 |
| Amag Pharmaceuticals, INC. | $16.60 | 2019 | |
| Medicem INC. | $16.04 | 2021 | |
| Avion Pharmaceuticals | $13.75 | 2023 | Balcoltra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Leite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.